Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
249.59
+2.46 (1.00%)
At close: Nov 20, 2026, 4:00 PM EST
250.00
+0.41 (0.16%)
After-hours: Nov 20, 2026, 7:55 PM EST
Biogen Revenue
Biogen had revenue of $2.80B in the quarter ending September 30, 2026, with 10.63% growth. This brings the company's total for the last twelve months to $10.30B, up 2.30% year-over-year. In the year 2025, Biogen had annual revenue of $9.89B with 2.22% growth. That makes Biogen the 1,442nd largest company in the world by revenue and 446th in the United States.
Revenue (ttm)
$10.30B
Revenue Growth
+2.30%
P/S Ratio
3.58
Revenue / Employee
$1,372,973
Employees
7,500
Market Cap
36.89B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Biogen breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.89B | 214.70M | 2.22% |
| Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | 14.38B | 925.00M | 6.88% |
| Dec 31, 2018 | 13.45B | 1.18B | 9.61% |
| Dec 31, 2017 | 12.27B | 825.10M | 7.21% |
| Dec 31, 2016 | 11.45B | 685.00M | 6.36% |
| Dec 31, 2015 | 10.76B | 1.06B | 10.93% |
| Dec 31, 2014 | 9.70B | 2.77B | 39.97% |
| Dec 31, 2013 | 6.93B | 1.42B | 25.66% |
| Dec 31, 2012 | 5.52B | 467.83M | 9.27% |
| Dec 31, 2011 | 5.05B | 332.21M | 7.04% |
| Dec 31, 2010 | 4.72B | 339.08M | 7.75% |
| Dec 31, 2009 | 4.38B | 279.84M | 6.83% |
| Dec 31, 2008 | 4.10B | 925.89M | 29.19% |
| Dec 31, 2007 | 3.17B | 488.57M | 18.21% |
| Dec 31, 2006 | 2.68B | 260.55M | 10.76% |
| Dec 31, 2005 | 2.42B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 67.38B |
| Pfizer | 63.62B |
| AstraZeneca | 62.38B |
| Sanofi | 57.89B |
| Novartis AG | 57.36B |
| Novo Nordisk | 50.70B |
| Bristol-Myers Squibb Company | 50.03B |
| GSK plc | 44.53B |
BIIB News
- 2 days ago - Clarity AD CSF Substudy Findings on Lecanemab Treatment and α-Synuclein Co-Pathology Presented at CTAD 2026 - PRNewsWire
- 3 days ago - Biogen, Eisai say LEADER findings show 76% lower rate of progression in AD - TheFly
- 3 days ago - New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026 - PRNewsWire
- 3 days ago - Biogen's anti-tau Alzheimer's drug benefits increase at 2 years - Reuters
- 3 days ago - Biogen says diranersen demonstrates increasing clinical benefit at two years - TheFly
- 3 days ago - Biogen's Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer's Disease - GlobeNewsWire
- 4 days ago - Biogen Transcript: Jefferies Global Healthcare Conference - Transcripts
- 4 days ago - New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026 - PRNewsWire